Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells

Yuanxuan Xia, Leila A. Mashouf, Russell Maxwell, Luke C. Peng, Evan Lipson, William Sharfman, Chetan Bettegowda, Kristin A Redmond, Lawrence R Kleinberg, Michael Lim

Research output: Contribution to journalArticle

Abstract

Background: Patients with melanoma can present with a hemorrhagic intracranial lesion. Upon resection, pathology reports may not detect any malignant cells. However, the hemorrhage may obscure their presence and so physicians may still decide whether adjuvant radiotherapy should be applied. Here, we report on the outcomes of a series of patients with melanoma with hemorrhagic brain lesions that returned with no tumor cells. Methods: All melanoma patients who had craniotomies from 2008 to 2017 at a single institution for hemorrhagic brain lesions were identified through retrospective chart review. Those who had pathology reports with no malignant cells were analyzed. Recurrence at the former site of hemorrhage and resection was the primary outcome. Results: Ten patients met inclusion criteria, and the median follow-up time was 8.5 (1.8-27.3) months. At the time of craniotomy, the median number of brain lesions was 3 (1-25). Two patients had prior craniotomies, eight had prior radiation, and six had prior immunotherapy to the lesion of interest. After surgery, one patient received stereotactic radiosurgery (SRS) to the resection bed. Only one patient developed subsequent melanoma at the resection site; this patient developed the lesion recurrence once and had not received postoperative SRS. Conclusion: Although small foci of metastatic disease as a source of bleeding for some patients cannot be excluded, melanoma patients with a suspected hemorrhagic brain metastasis that shows no tumor cells on pathology may benefit from close observation. The local recurrence risk in such cases appears to be low, even without adjuvant radiation.

Original languageEnglish (US)
Article number146
JournalSurgical Neurology International
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Adjuvant Radiotherapy
Melanoma
Neoplasm Metastasis
Brain
Craniotomy
Radiosurgery
Pathology
Hemorrhage
Recurrence
Radiation
Immunotherapy
Neoplasms
Observation
Physicians

Keywords

  • Brain metastasis
  • Hemorrhage
  • Melanoma
  • Negative pathology
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

@article{cd4046e418b7409a9d759c03b1f59e0b,
title = "Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells",
abstract = "Background: Patients with melanoma can present with a hemorrhagic intracranial lesion. Upon resection, pathology reports may not detect any malignant cells. However, the hemorrhage may obscure their presence and so physicians may still decide whether adjuvant radiotherapy should be applied. Here, we report on the outcomes of a series of patients with melanoma with hemorrhagic brain lesions that returned with no tumor cells. Methods: All melanoma patients who had craniotomies from 2008 to 2017 at a single institution for hemorrhagic brain lesions were identified through retrospective chart review. Those who had pathology reports with no malignant cells were analyzed. Recurrence at the former site of hemorrhage and resection was the primary outcome. Results: Ten patients met inclusion criteria, and the median follow-up time was 8.5 (1.8-27.3) months. At the time of craniotomy, the median number of brain lesions was 3 (1-25). Two patients had prior craniotomies, eight had prior radiation, and six had prior immunotherapy to the lesion of interest. After surgery, one patient received stereotactic radiosurgery (SRS) to the resection bed. Only one patient developed subsequent melanoma at the resection site; this patient developed the lesion recurrence once and had not received postoperative SRS. Conclusion: Although small foci of metastatic disease as a source of bleeding for some patients cannot be excluded, melanoma patients with a suspected hemorrhagic brain metastasis that shows no tumor cells on pathology may benefit from close observation. The local recurrence risk in such cases appears to be low, even without adjuvant radiation.",
keywords = "Brain metastasis, Hemorrhage, Melanoma, Negative pathology, Stereotactic radiosurgery",
author = "Yuanxuan Xia and Mashouf, {Leila A.} and Russell Maxwell and Peng, {Luke C.} and Evan Lipson and William Sharfman and Chetan Bettegowda and Redmond, {Kristin A} and Kleinberg, {Lawrence R} and Michael Lim",
year = "2018",
month = "1",
day = "1",
doi = "10.4103/sni.sni-140-18",
language = "English (US)",
volume = "9",
journal = "Surgical Neurology International",
issn = "2152-7806",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

TY - JOUR

T1 - Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells

AU - Xia, Yuanxuan

AU - Mashouf, Leila A.

AU - Maxwell, Russell

AU - Peng, Luke C.

AU - Lipson, Evan

AU - Sharfman, William

AU - Bettegowda, Chetan

AU - Redmond, Kristin A

AU - Kleinberg, Lawrence R

AU - Lim, Michael

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Patients with melanoma can present with a hemorrhagic intracranial lesion. Upon resection, pathology reports may not detect any malignant cells. However, the hemorrhage may obscure their presence and so physicians may still decide whether adjuvant radiotherapy should be applied. Here, we report on the outcomes of a series of patients with melanoma with hemorrhagic brain lesions that returned with no tumor cells. Methods: All melanoma patients who had craniotomies from 2008 to 2017 at a single institution for hemorrhagic brain lesions were identified through retrospective chart review. Those who had pathology reports with no malignant cells were analyzed. Recurrence at the former site of hemorrhage and resection was the primary outcome. Results: Ten patients met inclusion criteria, and the median follow-up time was 8.5 (1.8-27.3) months. At the time of craniotomy, the median number of brain lesions was 3 (1-25). Two patients had prior craniotomies, eight had prior radiation, and six had prior immunotherapy to the lesion of interest. After surgery, one patient received stereotactic radiosurgery (SRS) to the resection bed. Only one patient developed subsequent melanoma at the resection site; this patient developed the lesion recurrence once and had not received postoperative SRS. Conclusion: Although small foci of metastatic disease as a source of bleeding for some patients cannot be excluded, melanoma patients with a suspected hemorrhagic brain metastasis that shows no tumor cells on pathology may benefit from close observation. The local recurrence risk in such cases appears to be low, even without adjuvant radiation.

AB - Background: Patients with melanoma can present with a hemorrhagic intracranial lesion. Upon resection, pathology reports may not detect any malignant cells. However, the hemorrhage may obscure their presence and so physicians may still decide whether adjuvant radiotherapy should be applied. Here, we report on the outcomes of a series of patients with melanoma with hemorrhagic brain lesions that returned with no tumor cells. Methods: All melanoma patients who had craniotomies from 2008 to 2017 at a single institution for hemorrhagic brain lesions were identified through retrospective chart review. Those who had pathology reports with no malignant cells were analyzed. Recurrence at the former site of hemorrhage and resection was the primary outcome. Results: Ten patients met inclusion criteria, and the median follow-up time was 8.5 (1.8-27.3) months. At the time of craniotomy, the median number of brain lesions was 3 (1-25). Two patients had prior craniotomies, eight had prior radiation, and six had prior immunotherapy to the lesion of interest. After surgery, one patient received stereotactic radiosurgery (SRS) to the resection bed. Only one patient developed subsequent melanoma at the resection site; this patient developed the lesion recurrence once and had not received postoperative SRS. Conclusion: Although small foci of metastatic disease as a source of bleeding for some patients cannot be excluded, melanoma patients with a suspected hemorrhagic brain metastasis that shows no tumor cells on pathology may benefit from close observation. The local recurrence risk in such cases appears to be low, even without adjuvant radiation.

KW - Brain metastasis

KW - Hemorrhage

KW - Melanoma

KW - Negative pathology

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=85060612326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060612326&partnerID=8YFLogxK

U2 - 10.4103/sni.sni-140-18

DO - 10.4103/sni.sni-140-18

M3 - Article

AN - SCOPUS:85060612326

VL - 9

JO - Surgical Neurology International

JF - Surgical Neurology International

SN - 2152-7806

IS - 1

M1 - 146

ER -